Vivos Inks Definitive Deal for Florida Sleep Center, Eyes $6M Annual Revenue
VVOS is trading near its 52-week low of $0.24 (8.0% above the low).
Summary
Vivos Therapeutics has signed definitive agreements with South Palm Cardiovascular Associates to launch a regional Sleep & Airway Medicine Center in Palm Beach County, Florida. The deal formalizes the previously announced collaboration and gives Vivos a 75% majority stake in the new management services organization, AIM Florida. The initial team is expected to serve about 250 patients per month, generating up to $6 million in annual revenue with contribution margins of 30% or more. Revenue is not expected until Q1 2027, pending site selection, licensing, and staffing. This is a meaningful step for a company with only $1.8 million in cash and a going concern warning, as it provides a path to recurring revenue, though execution risk remains high.
At the time of this announcement, VVOS was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.24 to $4.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.